This week we respond to some listener feedback from Dr. Christopher Booth and use it to talk about how to be the best hematologist-oncologist. We also discuss the SADAL study on Selinexor for patients with relapsed refractory diffuse large B-cell lymphoma, as published in The Lancet Haematology. Finally, we interview Drs. Eva Katsoulakis and Michael Kelley on their recent paper out in the Journal of Clinical Oncology: Precision Oncology, titled "Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program". Selinexor: doi.org/10.1016/S2352-3026(20)30120-4 Annotation Services: doi.org/10.1200/PO.19.00118 Back us on Patreon! www.patreon.com/plenarysession Check out our YouTube channel: https://www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew